Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial

Merck & Co., Inc. (NYSE:MRK) is one of the top most undervalued low volatility stocks to buy now. On August 27, Merck & Co., Inc. (NYSE:MRK) announced that the first patient was dosed in the HERTHENA-Breast04 phase 3 trial that is evaluating “the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer with disease progression following endocrine and CDK4/6 inhibitor therapy in either the adjuvant or first-line metastatic settings.”

Discovered by Daiichi Sankyo, Patritumab deruxtecan is a specifically engineered HER3-directed DXd antibody drug conjugate (ADC) that is under joint development by Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.